Here is Bolton's role, he is actually a very high level and works with FDA relations:
So, I would think that he may have an inside track on the direction the FDA is going, enforcement discretion. He mentions the selling of CBD mass market, and the FDA would require effective QC. Kind of sounded like a done deal and I don't think he would have said that if that was not the direction the FDA was going.
This is minor compared to the Gottlieb clues that you provided in depth analysis for which boosted the confidence levels for approval. However, it's positive to see a GW Exec mention it. They have a bunch of active and new trials, I am curious to see if they involve other compounds with CBD. I'll see if I can come across the transcript for his speech.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.